We previously reported that on December 21, 2017, Genentech filed suit against Sandoz in the District of New Jersey based on Sandoz’s proposed rituximab biosimilar, Rixathon/GP2013. On April 23, 2018, Judge Renee Marie Bumb held an in-person status conference and set forth a preliminary injunction briefing schedule. The Court ordered the motion for preliminary injunction to be filed by May 4, 2018, opposition to be filed by June 4, 2018 and any reply to be filed by June 29, 2018. According to an order of the Court last month, a preliminary injunction trial is schedule for July 10, 2018.
Stay tuned to Big Molecule Watch for further updates.
The post Judge Sets Preliminary Injunction Briefing Schedule in Genentech v. Sandoz appeared first on Big Molecule Watch.